Hubbry Logo
Richard FuiszRichard FuiszMain
Open search
Richard Fuisz
Community hub
Richard Fuisz
logo
19 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Richard Fuisz
Richard Fuisz
Richard Fuisz
View on Wikipedia
from Wikipedia

Richard Carl Fuisz[pronunciation?] (born December 12, 1939) is an American physician, inventor, and entrepreneur, with connections to the United States military and intelligence community. He holds more than two hundred patents worldwide, in such diverse fields as drug delivery, interactive media, and cryptography, and has lectured on these topics internationally.[1] Fuisz is a member of the Board of Regents of Georgetown University,[2] where he and his brother created an annual scholarship honoring their deceased elder sibling, and established the first endowed professorship at the Georgetown University School of Medicine.[3]

Key Information

Early life and education

[edit]

Fuisz was born on December 12, 1939, in Bethlehem, Pennsylvania, to Anton Fujs, a Slovenian immigrant from Murska Sobota and Margaret Matuš, a Slovenian-American whose parents had migrated from Prekmurje.[3]

Fuisz and his older brother Robert graduated from Bethlehem Catholic High School before attending Georgetown University, where they both studied biology and eventually completed medical school.[4] Fuisz completed his internship and residency at the Harvard Medical School's Cambridge Hospital campus.[5]

Career

[edit]

After completing medical school and his residency, Fuisz served as a general physician and lieutenant commander in the U.S. Navy, where he was stationed at the White House during the Johnson administration.[3][4] Fuisz and his family hold dual citizenship in the United States and Slovenia, and Fuisz endowed the Richard and Lorraine Fuisz Library and the Zoltan Fuisz Scholarship Fund at Moravian Academy for children of Slovenian ancestry.[3]

Medcom

[edit]

In the 1970s, Fuisz and his brother co-founded Medcom, Inc., a New York-based firm producing educational and training materials for health-care providers and consumers; Fuisz played the role of a physician in government-subsidized public health films.[6] In 1971,[7] Medcom acquired California-based Trainex Corporation, which supplied medical personnel training materials to the Middle East and North Africa.[4] Fuisz learned Arabic so that he could better supervise Medcom's new division, and during this period Medcom became a top supplier of medical training to Middle Eastern militaries.[4] Fuisz served as president and CEO of Medcom from 1975 until 1982,[8] when the company was purchased by Baxter International, a supplier of hospital equipment, for $52 million.[4][9] Fuisz initially offered to stay on for a three-year transition period to introduce the new ownership to his clients, but he was instead fired by Baxter chief executive Vernon Loucks.[10]

After Medcom's sale and Fuisz's removal, business declined dramatically in the company's two biggest markets, the United States and Saudi Arabia, and profits plummeted.[9] Then, in 1985 Fuisz sued Baxter over his termination.

When Fuisz arrived at the Baxter offices in Deerfield, Illinois, to sign the settlement and collect his financial compensation of $800,000, Baxter CEO Loucks refused to meet with him; Fuisz later said that he realized at that moment "there was only one way this would end."[10] He claimed to have then spent $35,000 to obtain secret government documents describing Baxter's dealings with Syria, and he sent a 20-page memorandum to Baxter board members outlining his findings. He alleged that Baxter sold their Ashdod facility to Teva Pharmaceutical while simultaneously negotiating the construction of a similar plant in Syria, and that, for this reason, in 1989, they were removed from the Arab League's blacklist.[11][12] With the help of the American Jewish Congress, he brought the anti-boycott charges to the United States Department of Commerce Office of Anti-Boycott Compliance (OAC). In 1991, OAC referred the case to the Justice Department, resulting in the first-ever criminal prosecution of a company for violating anti-boycott laws in the U.S.[11] In 1993, though the prosecution was unable to prove Fuisz's allegations, Baxter pleaded guilty to illegal delivery of information about its Israeli business to Arab officials, which was prohibited under export control provisions of the EAA, and was assessed $6.5 million in fines and penalties.[10]

Folkon

[edit]

In the 1980s, Fuisz was involved in a number of business ventures in the Soviet Union through Leopoldina Import-Export Inc., an international business consulting firm, and Folkon, Ltd., an oil exploration company.[13][14] Working with a young Mikhail Khodorkovsky, then the head of the Young Communist League, Fuisz exported computers and other electronics to the Soviet Union through the Center for Scientific and Technical Creativity of the Youth,[15] and he would later claim that his business helped to supply computers to the KGB.[16][17]

In 1988, Fuisz was approached by Yuri Dubinin, the Soviet ambassador to the United States, to set up a modeling agency that would prepare young Soviet models for American markets.[15] The first model Fuisz was to oversee was Yulia Sukhanova, the first-ever Miss USSR, but hard-liners in the Moscow City Council obstructed Fuisz's efforts to secure Sukhanova's visa. With Khodorkovsky's assistance, he was able to smuggle Sukhanova out of the country, though upon reaching the U.S. she cut ties with Fuisz after a dispute over his commissions. In the first of two depositions regarding Fuisz's knowledge of the 1988 Lockerbie bombing, held in December 2000, Fuisz was prohibited from answering questions regarding the relationship between his Russian businesses and the Central Intelligence Agency – when asked if Folkon did any work for the CIA, whether it received any money from the CIA, or whether there were any links between the CIA and any of the companies operated by Fuisz, U.S. Attorney (DOJ) Anthony Coppolino raised objections precluding Fuisz's testimony on the grounds of state secrets privilege.[18] In the second deposition, held in January 2001, when asked to describe his interactions with high-level Soviet officials, Fuisz claimed to have difficulty separating information gained in his capacity as director of the modeling agency from information gained in "his employment by the government", and that he was "prohibited by a contract with the government" from providing further clarification.[19]

Allegations of arms sales to Iraq

[edit]

In January 1992, The New York Times published an article by journalist Seymour Hersh alleging that U.S. intelligence had helped to arm the Iraqi military during the Gulf War, naming Fuisz as its primary source.[20] The article described an affidavit Fuisz had submitted to the United States House Agriculture Subcommittee on Nutrition, Oversight, and Department Operations, which was investigating American heavy equipment manufacturer Terex Corp. Fuisz, who had been involved in business in the Middle East for many years, was representing a Saudi family interested in purchasing a heavy equipment company when he was given a tour of the Terex plant in Motherwell, Scotland in September 1987. During the tour, Fuisz noticed two large armor-plated vehicles painted in desert camouflage with specially attached steel backs; the plant manager allegedly told Fuisz that the vehicles were Scud missile launchers being manufactured for the Iraqi military, and that they were being smuggled by modifying their serial numbers to disguise them as civilian mining vehicles. When Fuisz questioned Terex Vice President David Langevin about the vehicles, he claims he was told that the shipments had been requested by the CIA, with the cooperation of British intelligence. Fuisz's allegations were corroborated by a former Terex employee also interviewed by the House Committee, who had been fired after raising questions about the company's bookkeeping.

Scud missiles were used extensively by Iraq during the Gulf War to strike coalition forces in Israel and Saudi Arabia. Fuisz claimed that he had attempted to bring Terex's arms deals to the attention of the United States House Energy Subcommittee on Oversight and Investigations in 1987, but committee chairman John Dingell had refused to act. Terex was (at the time) owned by General Motors (GM), a major political constituent in Dingell's home state of Michigan, and Dingell's wife was the granddaughter of a GM founder and a senior officer in the company's governmental relations department.[21] Fuisz did not press the issue again until Charlie Rose of the Agriculture Committee asked him for an affidavit; the Scud launchers were suspected of being funded with ear-marked agriculture money through the Atlanta branch of the Italian Banca Nazionale del Lavoro (BNL) – documents obtained in a 1989 raid on the bank revealed that Terex, through its independent British distributor, had sold dump truck chassis in 1988 to the Iraqi "Technical Corps for Special Projects, Project 395," a code name for Saddam Hussein's missile program.[22] Fuisz speculated that the Terex production was covered up out of fear of backlash from the patriotic demographic of American truck drivers, who drove vehicles manufactured almost exclusively by Fruehauf Corp., a wholly owned subsidiary of Terex.[22]

Both Terex and the CIA immediately denied any military relationship with Iraq, and in April 1992, Terex filed a $15 million libel suit against Hersh and Fuisz, claiming that Fuisz fabricated the story as retaliation against the company for declining to enter into a business deal.[23] In March 1993, the U.S. Department of Justice filed a Statement of Interest in the trial and invoked the state secrets privilege to bar Fuisz from testifying in his own defense.[24] The gag order claimed that the information Fuisz possessed was vital to the "nation's security or diplomatic relations", and could not be revealed "no matter how compelling the need for, and relevance of, the information", while empowering the government to "protect its interests in this case in the future" (effectively gagging Fuisz permanently).[25] In October 1994, the U.S. District Court for the District of Columbia upheld the Justice Department's claim of state secrets privilege and by 1996 the suit had been dismissed.[24] In December 1995, The New York Times issued a retraction and apology for Hersh's 1992 article, claiming that "neither The Times nor Mr. Hersh intended" to give the impression that Terex was supplying Scud missile launchers to Iraq, blaming errors made in the editorial process and "false information" supplied by Fuisz.[26] The retraction noted that a 16-month federal investigation had determined "there is no credible evidence" that Terex supplied military equipment to Iraq, affirming that "The Times has no evidence that contradicts the task force's findings"; this conclusion was supported by a separate investigation by the British House of Commons in 1996.[27] However, in December 2003, a 12,000 page dossier submitted by the Scottish newspaper Sunday Herald to the United Nations revealed that Terex, along with more than twenty other American firms, had in fact supplied Iraq with weapons technology during the 1990s; Scottish Labour MP Tam Dalyell called the document "of huge significance" in exposing "the hypocrisy of Blair and Bush."[28]

Fuisz Technologies Ltd.

[edit]

In June 1988, Fuisz founded Chantilly, Virginia-based medical technology firm Fuisz Technologies Ltd. (FT).[8] In December 1995 he took the company public – on the strength of Fuisz's patent for pills that would quickly dissolve in the mouth without water, the company had a successful initial public offering, and after its second offering in May 1996, its stock hit an all-time high of $31.50 per share.[6] Fuisz secured an agreement with Johnson & Johnson to develop a rapid-dissolve version of Tylenol, and thanks to his patents on "taste making" technologies that gave drugs more desirable flavors, Fuisz negotiated deals with SmithKline, Beecham, and Bayer for development of new versions of their over-the-counter products, as well as with Astra, Pfizer, and Merck for modified versions of certain prescription drugs.[29][30] FT also agreed to develop food products for British Sugar, ConAgra, General Mills, and Hershey Foods, among others.[31] Despite these lucrative arrangements, aggressive short-sellers began spreading rumors that Fuisz was being imprisoned by the FBI while being investigated by the IRS, and that his pills were so fragile they would disintegrate in shipping; by early 1997, the company's stock had plummeted to $5.62.[6][16] At around the same time, Fuisz resigned as CEO and hired Ken McVey, previously of Irish biotechnology firm Élan Corp., to replace him – though Fuisz retained 21% of the stock and his position as chairman of the company's board.

In January 1998, FT announced that it was selling its online drugstore to Richard Fuisz himself for $2.4 million, even though the business was worth only $50,000 on total sales of $60/month; Fuisz later claimed the purchase was a "white-knight act" performed in the interests of his shareholders.[16] The next month, Fuisz Technologies sued Élan, accusing its rival of stealing trade secrets and of reneging on a prior manufacturing deal with FT. Fuisz also personally sued Élan for breach of contract – Fuisz had reached a hand-shake agreement to sell his 4.2 million shares in FT to Élan for about $70 million in Élan stock, which Élan refused to honor, but only after completing an audit through which they acquired confidential documents describing FT's proprietary technology and corporate strategy.[29][32] News of the suit drove the company's share price from a high of $15.62 to $6.12,[30] thanks to the significant shortfalls caused by Élan's refusal to manufacture FT products.[29] In May, Fuisz threatened to fire McVey unless he resigned, blaming McVey's "bad management" for the company's struggles; McVey complied, Fuisz became acting CEO, and the stock fell again to $4.[16] In April 1999, the lawsuit was settled; in addition to purchasing an unspecified number of shares in FT from Fuisz, Élan finally agreed to a licensing and manufacturing agreement in which they would produce 1.2 billion tablet doses/year of FT products at their facility in Athlone, Ireland.[33] In July, Canadian drug firm Biovail purchased 49% of outstanding Fuisz Technologies common stock at $7/share, making FT a wholly owned subsidiary of Biovail.[34] By September, McVey, then living in a hotel in the Channel Islands, had filed two complaints of securities fraud with the Securities and Exchange Commission: first, to investigate whether Fuisz had knowingly and wilfully stolen assets from FT through his purchase of the online drugstore, and second, to investigate Patrick Scrivens, the firm's chief financial officer and former CIA public accountant,[35] who had sold all his FT stock at $15/share immediately before its big fall,[16] and became CFO of the online drugstore upon his resignation.[36]

Lockerbie bombing case

[edit]
Further information: Pan Am Flight 103

In 1998, Susan Lindauer submitted an affidavit to the United Nations claiming that she had met with 'a former intelligence operative,' naming Fuisz as her source, who disclosed that the Libyan government was wrongly accused of involvement in the 1988 Lockerbie bombing – she alleged that Fuisz had enlisted her help because he was being harassed by the IRS in retaliation for blowing the whistle on U.S. arms transfers to Iraq during the Gulf War.[37][38] Although it was initially reported in various international media that a state secrets gag order barred Fuisz from speaking about Lindauer's statement,[25][39] documents released in December 2013 by a member of Libyan Abdelbaset al-Megrahi's legal team show this to be only partially true.[17] In May 2000, Megrahi's lawyer Eddie MacKechnie wrote to Department of Justice Lockerbie prosecutor Brian Murtagh to determine whether Fuisz was indeed barred from testifying;[40] Murtagh replied that although Fuisz was still subject to a gag order related to the Terex libel suit, he was free to speak openly about the Pan Am bombing.[24] Fuisz insisted that this was not true, that he was subject to a "statutory obligation of secrecy" independent of the Terex litigation, and that he had been specifically advised by Murtagh and another DOJ lawyer to remain silent about Lockerbie.[41]

In September, MacKechnie asked Murtagh whether President Bill Clinton or CIA Director George Tenet could personally release Fuisz from his gag order;[42] CIA general counsel Robert Eatinger replied with a letter to Murtagh reaffirming that no court order prohibited Fuisz's testimony.[43] The next day, Fuisz called Eatinger's office seeking clarification of the letter – according to Eatinger, Fuisz described multiple briefings from CIA officers between 1988 and 1989 about various "security matters," in particular that Ahmed Jibril of the Popular Front for the Liberation of Palestine – General Command (PFLP-GC) was the primary suspect in the Lockerbie case; Eatinger responded that Fuisz was free to discuss the security briefings he received, but he was prohibited from revealing the identities of the CIA officers or discussing the purpose for which he received the briefings.[44] Fuisz was deposed first in December 2000, in the presence of a DOJ lawyer and two unnamed CIA officials, and again in January 2001, with three anonymous CIA officials presiding – although U.S. Attorney Anthony Coppolino invoked the state secrets privilege whenever the line of questioning approached details of Fuisz's relationship to the CIA, Fuisz confirmed that he had received multiple briefings from CIA agents in 1989 in which they informed him, among other things, that the PFLP-GC was responsible for the bombings; he further claimed that between 1990 and 1995 he was told separately by 10–15 high level Syrian officials, who were in regular contact with Ahmed Jibril, that the Palestinian group was to blame, though he was prohibited from clarifying the nature of his relationship to these officials.[18] In spite of Fuisz's testimony, Megrahi was sentenced to life imprisonment by the Scottish Court in the Netherlands in January 2001.[45]

Susan Lindauer and September 11 attacks

[edit]

After their initial introduction in 1994, Fuisz and Susan Lindauer continued to meet weekly to discuss her diplomatic contacts in the Middle East, including her work related to the lifting of U.S. sanctions against Libya and Iraq.[39] In 2000, the Sunday Herald acquired the text of Lindauer's 1998 affidavit. Lindauer claimed that Fuisz had infiltrated a network of Syrian terrorists tied to Iranian Hezbollah who were holding Americans hostage in Beirut, and that he was "first on the ground" in the investigation of the Lockerbie bombing because of his extensive contacts in Syria, but the CIA was destroying his reports instead of submitting them to investigators.[37] In May of that year, the Herald published an article alleging that Fuisz was the CIA Station Chief in Damascus during the 1980s;[25] when asked to comment on the Herald's claim and on his relationship to the CIA more generally, Fuisz remarked that "This is not an issue I can confirm or deny. I am not allowed to speak about these issues. In fact, I can't even explain why I can't speak about these issues."[39] Fuisz's meetings with Lindauer ended abruptly on September 11, 2001, the day of the September 11 attacks, due to what Fuisz described as an increasingly "seditious bent" to her discussions.

Kosmos Pharma and Fuisz LLC

[edit]

In 2000, the same year he was named to the board of directors of Bradley Pharmaceuticals,[5] Fuisz founded International Fluidics, another firm dedicated primarily to oral drug delivery systems; its name was changed to Kosmos Pharma in 2002.[citation needed] In order to acquire Fuisz's patents covering oral film strip technology, 'postage stamps' that dissolve instantly on the tongue, Kosmos was purchased by Monosol LLC in 2004, and Fuisz's son Joseph was named Monosol's senior Vice President.[46] Meanwhile, Fuisz continued to develop and secure patents through his family-owned private company, Fuisz LLC; in addition to health care innovations such as vaginal drug delivery,[47] thin-film-based smokeless tobacco and e-cigarettes,[2] and systems for monitoring addictive drug compliance,[48] Fuisz LLC also holds patents on wristwatches protected by encryption,[49] computer vision (including face and object recognition) and e-commerce, among other diverse technological fields.

Theranos

[edit]
Further information: Theranos

In 2011, the blood testing company Theranos and its CEO Elizabeth Holmes sued Fuisz and his sons, alleging that Fuisz had misappropriated a Theranos patent and used that information to file his own medical analyzer patent.[50] Theranos and Holmes were represented in the lawsuit by famed litigator David Boies. Boies alleged that the Fuiszes thought they could take advantage of Holmes because she was "young and female."[51]

Theranos separately made the same claims against its law firm McDermott Will & Emery, in a case that was dismissed.[52] Fuisz vociferously denied the allegations and defended himself pro se.[51]

Fuisz was credited in the book Bad Blood with connecting the author John Carreyrou with the former medical director of Theranos, exposing Theranos's fraudulent blood testing system.[53] John Carreyrou went on to write a series of articles for The Wall Street Journal, publicly revealing the Theranos fraud and intimidation tactics by Boies.[54][55] In the 2022 Hulu miniseries The Dropout, Fuisz was portrayed by William H. Macy.[56]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Richard Fuisz

View on Grokipedia
from Grokipedia
Richard Carl Fuisz (born December 12, 1939) is an American physician, inventor, and entrepreneur of Slovenian descent, recognized for pioneering pharmaceutical innovations, including thin-film technologies, and for amassing over 200 patents across , diagnostics, , and digital communications. Born in , to immigrant parents from Slovenia's region, Fuisz pursued medicine, becoming a licensed physician and educated at , before serving as a doctor and attaining the rank of in the U.S. with a White House posting. Transitioning to private enterprise, he founded ventures such as Fuisz Pharma LLC and Kosmos Pharma, developing systems resistant to abuse and rapid-dissolving oral films that facilitated products like medicated strips for buccal absorption, licensing these to pharmaceutical manufacturers for over-the-counter and prescription applications. Fuisz's career also encompassed medical training through Medcom Inc., early e-mail and interactive media patents via Fuisz Interactive Media, and reported service as a CIA operative, alongside political pursuits like a congressional run in and hosting a television . A philanthropist, he has endowed a professorship and library at Georgetown School of Medicine and scholarships at Moravian Academy, while maintaining personal interests in , piloting, and Arabic fluency.

Early Life and Education

Childhood and Family Background

Richard Carl Fuisz was born on December 12, 1939, in , to parents of Slovenian descent. His father, Anton Fujs (anglicized to Fuisz), immigrated from the village of Krog near in at age 17, while his mother, Margaret Matuš, was born in to parents who had emigrated from Dolenci in the region of . The family lived in South Bethlehem amid a community with notable Slovenian immigrant influences during Fuisz's early years in the 1940s and 1950s. He grew up in Lower Nazareth Township, attending Bethlehem Catholic High School and graduating in 1958. The Fuisz household preserved strong ties to Slovenian heritage, including a family visit to in the late , which Fuisz later described as brief and challenging due to political conditions under Yugoslav rule.

Academic and Professional Training

Richard Fuisz graduated from Bethlehem Catholic High School in , in 1958 before pursuing higher education at , where he studied biology. He subsequently enrolled in , earning a degree in 1965. After completing , Fuisz interned in , Georgia, and served as a general physician and in the U.S. Navy. He underwent additional postgraduate training at Harvard Medical School's Cambridge Hospital, which contributed to his specialization as a . This foundational medical and military experience preceded his transition into roles and inventive pursuits.

Medical and Inventive Career

Medcom Inc. and Early Medical Innovations

In 1968, Richard Fuisz, a physician, co-founded Medcom, Inc. in New York with his brother Robert Fuisz, also a physician, and Harold J. Kissell, a focused on creative production. The company pioneered audiovisual educational materials tailored for medical training, including films and programs designed to educate physicians and train pharmaceutical sales representatives on drug therapies and clinical practices. These innovations addressed a growing need for standardized, visually engaging , moving beyond traditional lectures and printed materials to formats that improved retention and comprehension among healthcare professionals. Medcom expanded rapidly during the 1970s, securing contracts with major pharmaceutical companies to produce customized training content, which facilitated more effective detailing of medications to doctors. The firm developed a significant international presence, particularly in , where it supplied educational programs adapted for local medical markets, contributing to its valuation growth. By emphasizing evidence-based content grounded in clinical data, Medcom's outputs supported pharmaceutical innovation dissemination while complying with regulatory standards for promotional materials. In 1982, acquired Medcom for $52 million, recognizing its established role in technology. This sale marked the culmination of Fuisz's early contributions to integrating tools into professional medical development, laying groundwork for subsequent advancements in health education delivery.

Folkon Industries

Folkon Ltd., established in 1987, operated as an oil exploration company under the leadership of Richard Fuisz, who served as its president and partner. The firm focused on international ventures, including activities in the during the late period. In legal documentation from 1995, Folkon was described as one of Fuisz's key enterprises, alongside Fuisz Technologies Ltd., with business operations partially conducted from his home office in , which factored into an insurance coverage dispute over premises liability. Fuisz maintained involvement with the company for over three decades, as indicated by professional records listing his ongoing partnership role. While primarily oriented toward resource extraction, Folkon's activities extended to technology applications, such as computer-related projects in during the mid-1980s, supporting a small team of 3-4 employees in the United States and approximately 10 in . The company's operations reflected Fuisz's broader entrepreneurial shift from medical innovations toward resource and international business pursuits, though specific production outputs or financial metrics for Folkon remain undocumented in . No patents are directly attributed to Folkon in available filings, distinguishing it from Fuisz's contemporaneous technology-focused entities.

Fuisz Technologies Ltd. and Tobacco Cessation Patents

Fuisz Technologies Ltd., founded by Richard C. Fuisz in June 1988 in , focused on innovative systems, including effervescent and rapid-dissolving formulations applicable to pharmaceuticals and consumer products. The company pursued patents in tobacco-related technologies emphasizing smokeless delivery mechanisms to enhance bioavailability without , aligning with strategies that facilitate transition from smoked to lower-risk alternatives. Key innovations included methods for producing extrudable tobacco compositions formed into dissolvable sheets, enabling controlled release via oral absorption. For instance, U.S. 10,334,872, issued June 25, 2019, covers a product in sheet form, an extrudable composition, and a process for manufacturing such products to deliver "super bioavailable" from to users, purportedly improving satisfaction and efficacy over traditional pouches or gums. Similarly, U.S. 9,125,434, issued September 8, 2015, details comparable sheet-based systems for delivery, building on techniques to achieve uniform distribution and prolonged dissolution. These patents addressed limitations in prior smokeless products by optimizing particle integration and matrix design for faster onset and sustained uptake, potentially supporting through substitution with non-inhaled forms. U.S. 10,602,769, issued March 31, 2020, further refines smokeless formulations for enhanced stability and user experience. Fuisz's work extended to complementary systems, such as vaporizable wax compositions under U.S. 10,709,165 (July 14, 2020), which enable aerosolized delivery without burning plant material. While marketed for , empirical validation of cessation efficacy remains tied to broader outcomes rather than product-specific trials. The technologies stemmed from Fuisz's expertise in polymer-based delivery, adapting principles from pharmaceutical to tobacco matrices for reduced exposure to pyrolysis byproducts. Later entities like Fuisz LLC, operated by Fuisz family members, built on these foundations, announcing related advancements such as improved pouch kinetics in 2013. Overall, Fuisz Technologies Ltd.'s contributions prioritized bioavailable transfer to mitigate smoking's health risks, though adoption has competed with established cessation aids like patches and .

Intelligence and National Security Involvement

CIA Connections and Asset Role

Richard Fuisz operated as a deep-cover CIA asset, with his intelligence activities intertwined with his medical and entrepreneurial pursuits in the during the and . As a physician and founder of Medcom Inc., Fuisz utilized his international business network to provide non-official cover for CIA operations, including the establishment of dummy corporations that employed agency personnel and enabled discreet intelligence gathering without reliance on embassy affiliations. This arrangement allowed assets to blend into commercial environments, facilitating interactions with regional contacts under the pretext of pharmaceutical and medical equipment sales. Fuisz's asset role extended to direct handling of back-channel communications and supervision of other operatives. From May 1995 to March 2003, he supervised , an asset conducting liaison with Libyan and Iraqi officials on behalf of U.S. intelligence interests. His operations in during the 1980s positioned him as a key figure for accessing high-level Syrian government sources, leveraging personal networks built through business for intelligence collection. Fuisz's as a legitimate entrepreneur and covert operative underscored the CIA's reliance on covers for in sensitive regions.

Lockerbie Bombing Case and Gag Order

Richard Fuisz, operating as a CIA asset in the during the and early , received briefings from the agency in the months following the December 21, 1988, bombing of over , , which killed 270 people. These briefings implicated the Popular Front for the Liberation of Palestine - General Command (PFLP-GC), a Syrian-based militant group, in organizing the attack as retaliation for U.S. naval actions in the . Fuisz later stated under oath that he could confirm no Libyan nationals were involved in planning or executing the bombing. In the fall of 1994, after Fuisz discussed his knowledge of the incident with congressional aide , the administration imposed a prohibiting him from speaking publicly about , with penalties including up to 10 years in prison and $250,000 fines for violations. The order stemmed from Fuisz's prior disclosures in unrelated legal proceedings regarding alleged illegal U.S. military equipment exports to via Corporation, but it explicitly extended to silencing his Lockerbie-related insights to protect classified intelligence sources and methods. Despite the restrictions, Lindauer submitted a sworn deposition to the Scottish detailing Fuisz's claims of Syrian culpability, though it was not admitted as in the 2000-2001 trial of Libyan suspect . Defense lawyers for Megrahi sought Fuisz's testimony during the trial preparations, securing depositions from him in late 2000 and 2001 that reiterated Syrian militant involvement, including specifics on bomb-making expertise and timing linked to PFLP-GC operations. However, these statements arrived too late for use in the proceedings, where Megrahi was convicted in January 2001 of based on evidence tying the attack to Libyan intelligence. Fuisz's persisted, limiting further public disclosure, though diplomatic efforts in 2004 urged its lifting to allow testimony potentially challenging the n attribution. His account aligned with early U.S. intelligence assessments favoring Iranian-Syrian proxies over , a narrative reportedly shifted amid geopolitical incentives following the 1990-1991 .

Collaboration with Susan Lindauer

, a former congressional staffer and self-described intelligence asset, first met Richard Fuisz in 1994 while investigating the 1988 bombing as part of her work on . Fuisz, positioned in the during the relevant period, shared detailed insights with Lindauer on the bombing's origins, asserting that Libyan involvement was a cover for other actors, including potential CIA-linked operations involving drug routes from . Lindauer has characterized Fuisz as her CIA handler, with their discussions forming the basis of her subsequent advocacy and affidavits challenging official narratives on . Following their initial exchange in fall 1994, the U.S. government imposed a gag order on Fuisz, prohibiting him from further public discussion of details under threat of severe penalties, including 10 years imprisonment or fines up to $250,000. Despite this restriction, Fuisz and Lindauer maintained regular contact, meeting approximately once a week from 1994 through early 2001, during which Fuisz reportedly supervised Lindauer's role as a liaison to Iraqi and Libyan intelligence contacts. These interactions focused on and intelligence, with Lindauer relaying messages aimed at facilitating FBI access to for anti-terrorism cooperation prior to the 2003 . In 1998, Lindauer submitted an affidavit to Lockerbie defense efforts, drawing directly from her conversations with Fuisz, who claimed definitive knowledge that was not involved and that the bombing implicated non-Libyan perpetrators tied to U.S. interests. Fuisz later confirmed in depositions the frequency and nature of their meetings but invoked the to withhold specifics on sensitive topics. Their , while centered on sharing, drew scrutiny amid Lindauer's 2004 indictment as an unregistered Iraqi agent—a case dismissed in 2009—highlighting tensions between official denials and asset testimonies on pre-war diplomacy. Lindauer's accounts, corroborated in part by Fuisz's acknowledged oversight role, portray their partnership as instrumental in unofficial U.S. efforts to avert regional conflicts through covert channels, though such claims remain contested due to the classified nature of Fuisz's CIA ties and Lindauer's legal history.

Pre-9/11 Intelligence Warnings

According to , who described Richard Fuisz as her CIA handler, Fuisz directed her in the months leading up to , 2001, to convey intelligence warnings about an imminent terrorist attack on the World Trade Center in southern involving hijacked airplanes. Lindauer stated that by August 2001, the urgency of the threat prompted Fuisz to explicitly warn her against traveling to , citing operational intelligence indicating the attack was "considered imminent." These directives were part of ongoing weekly meetings between Fuisz and Lindauer since 1994, focused on her back-channel diplomatic contacts in the and intelligence related to activities. Lindauer further claimed that Fuisz, along with associate Paul Hoven, volunteered specific 9/11-related warnings—derived from U.S. intelligence channels—to the prior to the attacks, including details on the planned operation and potential Iraqi connections, though the newspaper did not publish them. In her 2010 book Extreme Prejudice, Lindauer detailed how Fuisz's instructions emphasized the attack's scale and the involvement of planes as weapons, positioning these exchanges within broader U.S. intelligence efforts to monitor threats post-1993 World Trade Center bombing. Fuisz's role drew from his established CIA affiliations, including prior asset work on cases like the bombing, where he accessed classified sources under . These warnings align with declassified intelligence indicating U.S. agencies received multiple alerts about plotting aircraft-based attacks on U.S. soil in summer 2001, though specifics tying Fuisz directly remain unconfirmed in official reports like the findings, which noted systemic failures in information sharing. Lindauer's accounts, supported by witness testimony from Parke Godfrey during her 2004-2009 legal proceedings—where she faced charges as an unregistered Iraqi agent—assert she relayed Fuisz's to senior officials, including warnings as late as August 2001 of a "spectacular" strike on . Fuisz reportedly ceased contact with Lindauer post-9/11 amid disputes over her public disclosures.

Pharmaceutical Business Ventures

Kosmos Pharma and Effervescent Technologies

In 2000, Richard C. Fuisz co-founded Kosmos Pharma with his son , establishing the company in , to develop thin-film drug delivery systems for rapid oral absorption. These dissolvable films, often described as "postage stamp"-sized, were engineered to adhere to mucosal surfaces and release active ingredients quickly without water, targeting applications like for , where prototypes dissolved on the tongue for sublingual uptake. The technology leveraged Fuisz's prior expertise in dissolvable formulations, aiming to improve patient compliance through convenience and reduced swallowing difficulties. Kosmos Pharma's intellectual property included patents on uniform, non-self-aggregating thin films that enhanced and masked bitter tastes, positioning the company for partnerships in controlled-release pharmaceuticals. In 2004, MonoSol LLC acquired substantially all of Kosmos Pharma's assets, including its oral patent estate, to form MonoSol Rx and accelerate commercialization of fast-dissolving strips for drugs and consumer products. This acquisition integrated Fuisz's innovations into broader manufacturing, with MonoSol Rx later expanding production facilities in , for edible films. Parallel to thin-film advancements, Fuisz contributed to effervescent technologies through patents assigned to his ventures, such as formulations using acid-base couples to generate for rapid tablet disintegration in aqueous environments. These systems, detailed in U.S. patents like those for effervescent pharmaceutical compositions, facilitated effervescent-assisted delivery of antacids and other agents, improving dissolution rates and gastrointestinal absorption without mechanical chewing. Such innovations complemented Kosmos's non-effervescent films by offering alternative rapid-dissolve mechanisms, though primarily developed earlier under entities like Fuisz Technologies Ltd. Fuisz LLC is a privately held technology company founded by physician and inventor Richard C. Fuisz and his son Joseph M. Fuisz, with a primary focus on pharmaceutical innovations, systems, anti-abuse technologies, and medical devices. The company, headquartered in , serves as a vehicle for the Fuisz family's ongoing development following earlier ventures, emphasizing practical applications in healthcare such as effervescent formulations and specialized delivery mechanisms. Key developments under Fuisz LLC include advancements in non-invasive medical devices and diagnostic tools. In April 2022, affiliate Fuisz Pharma LLC announced the issuance of U.S. No. 11,298,223 for a non-invasive urological device designed to alleviate symptoms of (BPH) through targeted acoustic energy application, building on Richard Fuisz's prior work in therapeutic delivery. Earlier, in June 2021, Fuisz Pharma received a notice of allowance for claims related to breath-based diagnostic for detecting metabolic markers, with inventor Richard Fuisz highlighting its potential to enable non-invasive monitoring pending further validation. The company has also pursued patents in secure communication and wearable tech, such as U.S. Patent No. 7,911,349 issued in 2011 for a "cipher wristwatch system" enabling encrypted data transmission via timepiece interfaces, with Fuisz LLC actively seeking international protections in markets like . Additional innovations encompass biocompatible films for , as detailed in U.S. No. 8,241,661 assigned to Fuisz LLC in 2012, which describes variable cross-sectional area films for controlled release applications. In 2013, Fuisz LLC publicly recognized Richard C. Fuisz's induction into Georgetown University's 1789 Society, honoring his cumulative contributions to medical science and invention. Fuisz LLC's portfolio extends to and mitigation strategies, including objective criteria for REMS (Risk Evaluation and Mitigation Strategies) compliance announced in 2013, aimed at reducing abuse potential through tamper-evident formulations. These efforts reflect a sustained emphasis on empirical, device- and formulation-based solutions to clinical challenges, with over 200 patents attributed to Richard Fuisz across related entities, though independent verification of commercial viability remains limited to patent filings and announcements.

Allegations of Arms Sales to Iraq

In January 1992, Richard Fuisz alleged that Corporation, a U.S.-based manufacturer, had supplied modified high-mobility trucks to that were adapted into mobile launchers for Scud missiles, in violation of U.S. export controls during the late 1980s Iran- War period. Fuisz claimed to have personally observed two such armored vehicles at 's plant in , , in September 1987, where serial numbers had been altered to disguise them as civilian mining equipment, and that over 100 similar vehicles were shipped annually to starting that year. These assertions formed the basis for reporting in a New York Times article by , which cited anonymous intelligence sources including Fuisz, implying U.S. complicity in bolstering 's missile capabilities through transfers. Fuisz further testified before a U.S. Agriculture subcommittee on July 2, 1992, during an investigation into potential illegal pre-Gulf arms to , asserting that the transactions involved (Terex's parent at the time) and were facilitated with knowledge of their military end-use, potentially linked to CIA and British intermediaries. He reported contacting the U.S. Commerce Department in fall 1990 about the shipments but was directed toward media disclosure due to political sensitivities. Fuisz portrayed the deals as part of broader U.S. support for Saddam Hussein's regime against , including equipment that enhanced Iraq's ability to deploy chemical and . Terex Corporation vehemently denied the claims, stating that their exports were strictly civilian earth-moving machinery compliant with U.S. regulations and not convertible to missile transporters without extensive modification beyond Iraqi capabilities. In April 1992, filed a $15 million libel suit against Fuisz, Hersh, and , alleging the accusations were fabricated as retaliation for Terex's refusal of a from Fuisz to represent them in , constituting a deliberate smear campaign with reckless disregard for truth. Court filings described Fuisz's statements as portraying Terex as criminal violators of U.S. law aiding Iraq's military during the buildup. The controversy escalated when published an editors' note on December 7, 1995, acknowledging that the original reporting implied supplied Scud launchers, a charge unsupported by and leading to the paper's settlement with ; both and the CIA maintained no military ties to in those transactions. Fuisz's provider initially refused coverage for his defense, prompting a separate 1995 appellate case where the Fourth Circuit ruled in his favor, mandating defense under the policy due to potential claims amid the allegations. Despite the legal disputes, no criminal charges arose against , and Fuisz's allegations highlighted tensions over U.S. dual-use exports to in the , though subsequent investigations found no direct proof of intentional arms diversion in this instance.

Theranos Patent Lawsuit and Industry Skepticism

In October 2011, , Inc. and its founder filed a in the U.S. District Court for the Northern District of against Richard C. Fuisz, his sons John R. Fuisz and Joseph M. Fuisz, and Fuisz Technologies, Ltd. (later involving Fuisz Pharma LLC), alleging misappropriation, , and . claimed that John Fuisz, a longtime family friend and neighbor who had briefly consulted for the company in 2004, had accessed confidential details about its proprietary technology for analyzing small blood samples via during conversations with Holmes. The suit accused the Fuisz family of using this information to file U.S. Application No. 11/898,128 in September 2006, which culminated in the issuance of U.S. Patent No. 7,766,612 (the '612 patent) on August 3, 2010, covering methods for drawing blood into a cartridge using capillary forces without external pressure. argued that the '612 patent improperly derived from its secrets and sought to have Holmes named as a co-inventor while invalidating the Fuisz claims. Fuisz Pharma LLC responded by initiating a countersuit on November 1, 2011, in the U.S. District Court for the District of , accusing of infringing the '612 through its blood-testing devices, such as the Edison and systems, which purportedly used similar capillary-based sample handling. The case was transferred to and consolidated with ' action, leading to protracted discovery battles over attorney-client privilege, sealed documents, and allegations of unethical conduct by ' counsel . Fuisz maintained that the stemmed from independent invention, predating any alleged disclosures, and highlighted parallels between the '612 and ' own secretive filings, which had been placed under a order by the U.S. and Trademark Office. The disputes narrowed to inventorship and validity claims, with a scheduled but ultimately avoided through a confidential settlement in December 2013, after which dropped its misappropriation allegations without admitting fault. Parallel to the litigation, Richard Fuisz voiced early industry skepticism toward ' technological claims, viewing them as implausible given established limits in blood analysis from tiny volumes. As a veteran inventor with over 100 in medical devices, Fuisz collaborated with fellow doubters, including Stanford pharmacologist Phyllis Gardner, who in the early 2010s reinforced his concerns that Holmes' promises of revolutionizing diagnostics from finger-prick samples defied biochemical realities. Fuisz's suspicions intensified after analyzing ' patent secrecy and demo videos, leading him to question the company's partnerships with and its FDA validations. By 2015, he contributed to investigative efforts by sharing documents and insider contacts with Journal reporter , aiding the exposure of ' inaccuracies in 2015–2016 reporting that revealed reliance on commercial analyzers rather than proprietary tech. This , rooted in Fuisz's expertise rather than personal animus—despite the lawsuits' acrimony—underscored broader industry wariness, including from pathologists who noted the '612 's challenges to ' novelty claims.

Later Career and Innovations

Recent Biotechnology Initiatives

In the later stages of his career, Richard C. Fuisz continued to advance biotechnology through Fuisz Pharma LLC and affiliated entities, focusing on innovative drug delivery systems and medical devices. A key initiative involved the development of uniform thin films for rapid-dissolve applications in pharmaceuticals, culminating in U.S. Patent 10,888,499, issued on May 12, 2020, which describes thin films with non-self-aggregating uniform heterogeneity suitable for drug delivery. This technology builds on prior work in oral thin films, enabling precise dosing and improved bioavailability for active pharmaceutical ingredients. Similarly, U.S. Patent 10,730,207, issued August 4, 2020, outlines processes for manufacturing pharmaceutical films, emphasizing scalable production methods for biotech applications such as sublingual and buccal administrations. Fuisz's efforts extended to and consumer health technologies, including heat-not-burn devices for alternatives. On August 9, 2021, Fuisz announced the issuance of a for next-generation heat-not-burn device architecture, aimed at reducing harmful emissions while maintaining user satisfaction, aligning with broader trends in delivery. This initiative reflects ongoing collaboration with industry partners like Philip Morris Products S.A., as seen in related uniform film patents assigned to them. Another notable development was in urological , with Fuisz Pharma securing U.S. issuance on April 18, 2022, for a non-invasive device designed to mitigate symptoms of (BPH). The device employs targeted energy application to alleviate urinary obstruction without surgical intervention, addressing a common age-related condition affecting millions. Earlier in 2021, Fuisz Pharma received a notice of allowance for advancements in bodily fluid analyzer programming, enhancing remote monitoring and data integration for biotech diagnostics. These initiatives underscore Fuisz's persistent emphasis on practical, -protected solutions in pharmaceutical , despite his advanced age.

Ongoing Patents and Contributions

Richard C. Fuisz has maintained active contributions to pharmaceutical and fields through ongoing filings and issuances focused on mechanisms and related medical devices. In 2022, he co-invented an oral soluble composition designed for the delivery of active pharmaceutical agents, involving the deposition and drying of film-forming materials in structured wells to enable rapid dissolution upon . This builds on prior effervescent and thin-film technologies, aiming to improve and patient compliance for therapeutics. Similarly, a 2021 issuance covers methods and compositions for producing oral soluble films containing active agents, emphasizing scalable processes for biotech applications. Fuisz's recent work extends to vaporization systems with potential biotechnology implications, such as heaters incorporating air preheating elements to enhance efficiency in delivering vaporized botanicals or tobacco-derived waxes. A pending application from 2021 details a vaporizer heater with a tunnel structure and resistive elements for precise , supporting controlled release of active compounds. In February 2025, a was issued for a vaporizer specifically tailored for botanical sticks, featuring modular housing, electronic controls, and individual heaters to facilitate of vaporized substances, which could apply to medicinal botanicals. These developments reflect ongoing efforts via Fuisz Technologies Ltd. to advance non-combustible delivery platforms, with over 100 issued patents in related areas as of 2021, including heat-not-burn architectures announced that year. Through Fuisz LLC and affiliated entities, these patents underscore contributions to transmucosal and inhalation-based , prioritizing innovations in enhancement and device integration for therapeutic agents. Pending filings, such as those for vaporizable wax compositions in 2021, indicate continued exploration of stable, containerized formulations for biotech products. Fuisz's portfolio, exceeding 200 worldwide, continues to evolve with emphases on practical, empirically validated systems rather than unproven claims, as evidenced by licensed technologies in pharma packaging and analyte-related metadata consolidation.

References

  1. http://www.fuisz.com/images/SlovenesUSA1.pdf
  2. https://patents.justia.com/inventor/richard-fuisz
  3. https://patents.justia.com/inventor/richard-c-fuisz
  4. https://www.inc.com/peter-cohan/6-warning-signs-that-elizabeth-holmes-is-trouble-says-psychiatrist-who-has-known-her-since-childhood.html
  5. https://www.washingtonpost.com/archive/business/1996/07/15/they-may-be-selling-fuisz-technologies-short/22fdda14-7510-4609-93e4-03fbfa13bafb/
  6. https://manufacturingchemist.com/fuisz-pharma-patents-drug-film-formulations--81875
  7. https://thecinemaholic.com/was-richard-fuisz-really-elizabeth-holmes-neighbor-where-is-he-now/
  8. https://www.mcall.com/2022/04/02/the-dropout-stars-allentown-native-amanda-seyfried-as-elizabeth-holmes-the-theranos-scandal-has-another-lehigh-valley-connection-you-never-heard-about/
  9. https://www.mcall.com/1992/01/29/whistle-blower-left-lv-for-career/
  10. https://www.doximity.com/pub/richard-fuisz-md
  11. https://health.usnews.com/doctors/richard-fuisz-1123597
  12. https://www.fuisz.com/images/SlovenesUSA1.pdf
  13. https://www.nytimes.com/1972/03/21/archives/education-used-in-drug-sales.html
  14. https://www.chicagotribune.com/1993/03/26/6-million-from-baxter/
  15. https://www.forbes.com/forbes/1997/0421/5908070a.html
  16. https://www.mcall.com/1987/11/12/personalities-64/
  17. https://caselaw.findlaw.com/court/us-4th-circuit/1300756.html
  18. https://law.justia.com/cases/federal/appellate-courts/F3/61/238/493261/
  19. https://www.megrahiyouaremyjury.net/wp-content/uploads/2013/12/Fuisz-documents-release.pdf
  20. https://www.washingtonpost.com/archive/business/1999/03/01/fuisz-technologies-seeks-a-remedy-for-a-falling-stock-price/c404083c-445e-45ed-aa6d-17f9c3e246cd/
  21. http://www.fuisz.com/patents.html
  22. https://patents.google.com/patent/WO2011011168A1/en
  23. https://www.prnewswire.com/news-releases/fuisz-tobacco-announces-issuance-of-patent-for-improved-nicotine-delivery-from-a-tobacco-pouch-224847122.html
  24. https://www.prnewswire.com/news-releases/fuisz-tobacco-announces-patent-allowance-for-new-tobacco-pouch-system-to-improve-satisfaction-208463951.html
  25. https://www.crunchbase.com/organization/fuisz
  26. https://www.channel4.com/news/lockerbie-bombing-libya-palestine-cia-murder-thatcher
  27. https://www.oxygen.com/true-crime-buzz/who-was-elizabeth-holmes-spiteful-neighbor-richard-fuisz
  28. https://kboo.fm/media/11592-lindauer-knocks-it-out-park-axgain
  29. https://www.sdnl.nl/shimura/libya.html
  30. https://www.the-independent.com/news/world/politics/revealed-us-knew-of-other-lockerbie-suspects-9018938.html
  31. https://www.independent.co.uk/news/world/politics/revealed-us-knew-of-other-lockerbie-suspects-9018938.html
  32. https://www.telegraph.co.uk/news/worldnews/northamerica/usa/10532134/CIA-held-Syrian-militants-responsible-for-Lockerbie-bombing.html
  33. https://www.lrb.co.uk/the-paper/v29/n12/hugh-miles/inconvenient-truths
  34. https://inteltoday.org/2016/09/01/cia-asset-dr-richard-fuisz-terex-lockerbie/
  35. https://inteltoday.org/2017/09/01/one-year-ago-cia-asset-dr-richard-fuisz-terex-lockerbie/
  36. https://www.dailykos.com/stories/2004/3/11/19158/-
  37. https://www.nytimes.com/2004/08/29/magazine/susan-lindauer-s-mission-to-baghdad.html
  38. https://www.scoop.co.nz/stories/HL0901/S00210/feds-drop-case-against-accused-iraqi-agent.htm
  39. https://keywiki.org/Susan_Lindauer
  40. https://www.scoop.co.nz/stories/HL1103/S00072/lockerbie-diary-gadhaffi-fall-guy-for-cia-drug-running.htm
  41. https://www.scoop.co.nz/stories/HL1107/S00207/911-starting-over-with-the-truth-part-one.htm
  42. https://www.fbcoverup.com/docs/library/2012-08-13-Susan-Lindauer-AFFIDAVIT-Vancouver-Hearings-on-9-11-Veterans-Today-Aug-13-2012.pdf
  43. https://www.scoop.co.nz/stories/HL0806/S00263/911-prediction-revealed-at-lindauer-hearing-in-nyc.htm
  44. https://dissidentvoice.org/2011/09/cia-told-new-york-times-about-911-warnings-command-negligence-ny-times-lied/
  45. https://inteltoday.org/2019/01/13/cia-issues-posthumous-apology-after-new-evidence-clears-abdel-baset-al-megrahi-of-involvement-in-lockerbie-attack-when-parody-beats-justice/
  46. https://www.metabunk.org/threads/susan-lindauer.2494/
  47. https://www.washingtonpost.com/archive/business/2002/09/16/kosmos-pharma-develops-a-dose-of-convenience/3e4f78e8-fffe-442c-8871-a92f753e894b/
  48. https://www.washingtonpost.com/archive/business/2002/09/16/in-profile/c4c22407-7e82-4a93-b1b4-9a25d026a4e2/
  49. https://patents.google.com/patent/US7425292B2/en
  50. https://manufacturingchemist.com/monosol-and-kosmos-pharma-to-commercialise-oral-film-products-34818
  51. https://www.sec.gov/Archives/edgar/data/1398733/000104746907007408/a2178523zs-1a.htm
  52. https://aquestive.com/film-based-drug-development-and-manufacturing/
  53. https://patents.justia.com/patents-by-us-classification/424/466?page=7
  54. https://patents.google.com/patent/US5622719A/en
  55. https://patents.google.com/patent/EP1082106A4/en
  56. http://www.fuisz.com/
  57. https://synapse.patsnap.com/organization/3641a5a0a7b9bb1529839724eeac2c81
  58. https://www.globenewswire.com/news-release/2022/04/18/2423655/0/en/Fuisz-Pharma-LLC-Announces-Patent-Issuance-for-its-Non-Invasive-Urological-Device-to-Mitigate-the-Symptoms-of-Benign-Prostate-Hyperplasia-BPH.html
  59. https://finance.yahoo.com/news/fuisz-pharma-announces-receipt-notice-120000312.html
  60. https://www.prnewswire.com/news-releases/fuisz-announces-patent-issuance-for-cipher-wristwatch-system-170156116.html
  61. https://patents.google.com/patent/US8241661B1/en
  62. https://www.prnewswire.com/news-releases/fuisz-llc-announces-induction-of-richard-c-fuisz-md-into-georgetown-universitys-1789-society-199338551.html
  63. https://www.biospace.com/fuisz-pharma-announces-availability-of-objective-rems-criteria-for-opioids
  64. https://www.mcall.com/1992/01/29/us-group-built-scud-launchers-man-says-equipment-made-for-iraq/
  65. https://www.mcall.com/1992/07/02/ex-bethlehem-resident-testifies-about-covert-arms-shipments/
  66. https://www.nytimes.com/1992/01/26/world/us-secretly-gave-aid-to-iraq-early-in-its-war-against-iran.html
  67. https://law.resource.org/pub/us/case/reporter/F3/061/61.F3d.238.94-2120.html
  68. https://www.courtlistener.com/docket/4178722/theranos-inc-v-fuisz-technologies-ltd/
  69. https://arstechnica.com/science/2016/11/the-personal-bloodbath-behind-theranos-rise-and-fall/
  70. https://www.casemine.com/judgement/us/5914f783add7b04934995a87
  71. https://law.justia.com/cases/federal/district-courts/california/candce/5:2011cv05236/246994/254/
  72. https://www.casemine.com/judgement/us/5914e66cadd7b0493490e391
  73. https://www.govinfo.gov/content/pkg/USCOURTS-cand-5_11-cv-05236/pdf/USCOURTS-cand-5_11-cv-05236-6.pdf
  74. https://arstechnica.com/tech-policy/2019/03/theranos-how-a-broken-patent-system-sustained-its-decade-long-deception/
  75. https://knowledge.wharton.upenn.edu/podcast/knowledge-at-wharton-podcast/the-secrets-and-lies-that-sunk-theranos/
  76. https://www.nytimes.com/2025/10/03/science/phyllis-gardner-dead.html
  77. https://www.corporatecrimereporter.com/news/200/john-carreyrou-bad-blood-theranos/
  78. http://www.fuisz.com/new.html
  79. https://patents.justia.com/patent/20230363453
  80. https://patents.justia.com/patent/12213517
Add your contribution
Related Hubs
User Avatar
No comments yet.